SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing intense volatility as investors debate whether the stock is a distressed value play or a declining brand caught in a "go woke, go broke" narrative. While some traders are aggressively shorting the stock amid weak consumer sentiment and concerns over long-term relevance, others are accumulating shares, citing a significant dividend yield and potential upside from tariff refunds.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors weigh the potential long-term financial and operational fallout from a major multi-state trial concerning allegations of harm to younger users. While some market participants view the pullback as a buying opportunity given the company's strong core ad business and ongoing AI infrastructure investment, others remain cautious, debating whether regulatory risks and high capital expenditures could weigh on the stock's performance.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on the company's progress toward a Q4 BLA submission for its prostate cancer therapy, fueling significant discussion regarding its potential $10-16 billion market opportunity. The community is actively debating the stock's valuation disconnect and institutional accumulation, with many closely watching upcoming conference presentations and clinical data as key catalysts for a potential breakthrough.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist is trending as retail investors rally behind the stock's recent patent settlement with Samsung, viewing it as a catalyst for broader litigation success and potential future deals with other major memory manufacturers. Community members are actively sharing analysis on patent litigation, discussing the tight short interest that could fuel a squeeze, and debating the company's valuation as a key player in AI infrastructure.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing high volatility as traders react to a strong earnings report and aggressive growth guidance, while the community remains sharply divided between those betting on long-term AI infrastructure tailwinds and others shorting the stock due to concerns over valuation and insider selling. The stock's recent price swings and heavy trading volume have turned it into a focal point for both momentum traders and those debating the sustainability of its current market premium.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is experiencing significant volatility and retail frustration as investors grapple with weak forward guidance, ongoing debt concerns, and perceived algorithmic manipulation. While some traders are attempting to buy the dip, others are actively exiting their positions, citing a lack of confidence in the current management and broader sector headwinds like rising oil prices and geopolitical instability.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as bond market participants aggressively debate the outlook for long-term yields amid a cooling labor market, geopolitical tensions, and concerns over U.S. fiscal sustainability. The community is heavily split, with some traders betting on a sharp reversal as inflation potentially fades, while others fear a structural regime change that could push Treasury yields to fresh multi-decade highs.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as investors digest record quarterly revenue and rising commercial momentum, fueling intense speculation about a potential short squeeze and long-term valuation rerating. Community discussions are heavily focused on the company's expanding ATC network, the upcoming NSCLC clinical data, and the potential for a strategic acquisition by big pharma.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is experiencing significant downward pressure as investors closely monitor escalating geopolitical tensions and heightened skepticism regarding the company's financial stability. The community remains deeply polarized, with active debates surfacing around the firm's leadership, potential political impacts on valuation, and broader concerns over the company's long-term business viability.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is currently trending due to a combination of strong analyst sentiment and high-conviction institutional backing, fueling community debate over its premium valuation versus long-term growth potential. Investors are actively discussing the stock's volatility in the context of the broader AI infrastructure spending cycle, with many analyzing its role in high-speed connectivity while tracking technical support levels during recent price fluctuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics is trending due to a regulatory pivot where the FDA expressed willingness to review a major BLA amendment containing 24-month clinical data, potentially leading to a PDUFA date extension. The community is heavily focused on the high short interest and the prospect of a massive short squeeze as analysts significantly raise price targets following this path to a refined upper-limb indication.

Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom

Capricor shares are rising after the FDA signaled flexibility to review 24-month HOPE-3 data in an amended BLA supporting a narrower upper-limb indication, with the agency set to extend the Aug. 22 PDUFA date. Goldman Sachs also raised its stake by 73% to 1.58 million shares worth $38 million, adding to bullish sentiment around the regulatory path.

Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom 

Equity

Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.

CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm

CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm PR Newswire RADNOR, Pa., Aug. 16, 2026 Did you buy CAPR securities...

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact...

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman PR Newswire SAN FRANCISCO, Aug. 14, 2026...

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Capricor Therapeutics, Inc. (Capricor) (NASDAQ: CAPR) on behalf of those who purchased or acquired...

The Money Machine Is Back, as Biotech, AI, and Tech Names Explode

Today’s stock market coverage illustrates two very different kinds of momentum. NeOnc (NASDAQ:NTHI), MDxHealth (NASDAQ:MDXH), and Capricor Therapeutics (NASDAQ:CAPR) are fundamentally driven healthcare stories, where clinical data, regulatory decisions, diagnostics adoption and cash runway determine whether today's enthusiasm can become a durable rerating, while Wetour Robotics (NASDAQ:WETO), Onfolio Holdings (NASDAQ:ONFO), and Creative Global Technology Holdings (NASDAQ: CGTL) are much more structure-sensitive.

Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval

Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.read more...

CAPR’s FDA Showdown Is Here: The Advisory Committee Said No, But the Real Decision Hasn’t Happened Yet

The market may be treating Capricor Therapeutics (NASDAQ:CAPR) as if the July 29 FDA advisory committee vote delivered a knockout blow, but it didn't. It delivered a major setback, but the actual regulatory story appears to be considerably more complicated and, with the Deramiocel BLA still under active FDA review and a PDUFA action date of August 22, the most important decision has yet to be made.

CAPR Stock Explodes Premarket: Cantor Flips Bullish, Sees 278% Upside On Deramiocel FDA Path

Cantor Fitzgerald upgraded Capricor to ‘Overweight’ from ‘Neutral’ and raised its price target to $28 from $3.50, just weeks after the firm slashed its price target to $3.50 from $62.


S&P 500, Nasdaq Futures Pause Near Record Highs: Why SPCX, AMAT, SNDK, CSCO, CAPR, SLS, ONDS Stocks Are In Focus

Retail sentiment on Stocktwits remained improved to ‘bullish’ on SPY and remained ‘bearish’ on QQQ.


Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are closely watching the upcoming FDA PDUFA date for news on potential BLA amendment acceptance and review timeline extensions.

Significant increases in holdings by major firms like Goldman Sachs have fueled bullish sentiment and institutional backing expectations.

High borrow rates and aggressive short-selling behavior have created expectations for a rapid covering event if key price levels break.

Debates persist regarding the transparency of the FDA's regulatory process and the reliability of previously submitted clinical trial data.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.10	--	--	N/A
Q2 '26	-$0.59	-$0.70	-18.87%	MISSED
Q1 '26	-$0.51	-$0.59	-16.26%	MISSED
Q4 '25	-$0.51	-$0.62	-21.81%	MISSED
Q3 '25	-$0.55	-$0.54	1.22%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings